These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 27780780)

  • 1. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
    Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
    J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local Ablative Therapies in Oligometastatic NSCLC: New Data and New Directions.
    Lang P; Gomez DR; Palma DA
    Semin Respir Crit Care Med; 2020 Jun; 41(3):369-376. PubMed ID: 32450591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
    Jairam V; Park HS; Decker RH
    Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Juan O; Popat S
    Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic options for oligoprogressive non-small cell lung cancer].
    Gustin P; Botticella A; Tselikas L; Mercier O; Le Péchoux C; Levy A
    Rev Mal Respir; 2019 Apr; 36(4):519-526. PubMed ID: 31010758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies.
    Jongbloed M; Khosla AA; Bartolomeo V; Jatwani K; Singh R; De Ruysscher DKM; Hendriks LEL; Desai A
    Curr Oncol Rep; 2024 Jan; 26(1):80-89. PubMed ID: 38175464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.
    Guerrero E; Ahmed M
    Lung Cancer; 2016 Feb; 92():22-8. PubMed ID: 26775592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
    Dohopolski M; Iyengar P
    Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Significance of Surgery for Oligometastatic and Oligoprogressive Non-small Cell Lung Cancer].
    Schmid S; Passlick B
    Zentralbl Chir; 2017 Sep; 142(S 01):S38-S43. PubMed ID: 28958109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer: Theory and Practice.
    Rusthoven CG; Yeh N; Gaspar LE
    Cancer J; 2015; 21(5):404-12. PubMed ID: 26389766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
    Bansal P; Rusthoven C; Boumber Y; Gan GN
    Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease.
    Ning MS; Gomez DR; Heymach JV; Swisher SG
    Transl Lung Cancer Res; 2019 Feb; 8(1):97-106. PubMed ID: 30788239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer.
    Tam A; Eustace N; Kassardjian A; West H; Williams TM; Amini A
    Surg Oncol Clin N Am; 2023 Jul; 32(3):497-514. PubMed ID: 37182989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art.
    Franceschini D; De Rose F; Cozzi S; Franzese C; Rossi S; Finocchiaro G; Toschi L; Santoro A; Scorsetti M
    Crit Rev Oncol Hematol; 2020 Apr; 148():102894. PubMed ID: 32062314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer.
    Shultz DB; Diehn M; Loo BW
    Semin Radiat Oncol; 2015 Apr; 25(2):78-86. PubMed ID: 25771411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
    Iyengar P; All S; Berry MF; Boike TP; Bradfield L; Dingemans AC; Feldman J; Gomez DR; Hesketh PJ; Jabbour SK; Jeter M; Josipovic M; Lievens Y; McDonald F; Perez BA; Ricardi U; Ruffini E; De Ruysscher D; Saeed H; Schneider BJ; Senan S; Widder J; Guckenberger M
    Pract Radiat Oncol; 2023; 13(5):393-412. PubMed ID: 37294262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer: Past, Present, and Future.
    McCall N; Higgins K
    Oncology (Williston Park); 2021 Jun; 35(6):313-319. PubMed ID: 34139791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligoprogression in non-small cell lung cancer: a narrative review.
    Nguyen KT; Sakthivel G; Milano MT; Qiu H; Singh DP
    J Thorac Dis; 2022 Dec; 14(12):4998-5011. PubMed ID: 36647502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local ablative therapy of oligoprogressive TKI-treated thyroid cancer.
    Porcelli T; Sessa F; Luongo C; Salvatore D
    J Endocrinol Invest; 2019 Aug; 42(8):871-879. PubMed ID: 30628046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.